Randomized Trial Comparing Terazosin 5 mg Daily and Doxazosin GITS 4 mg Daily for Trial Without Catheter in Acute Urinary Retention With Long Term Follow up
Information source: Hospital Authority, Hong Kong
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Prostatic Hyperplasia; Urinary Retention
Intervention: Doxazosin GITS (Cardura XL) (Drug); Terazosin (Hytrin) (Drug)
Phase: N/A
Status: Terminated
Sponsored by: Hospital Authority, Hong Kong Official(s) and/or principal investigator(s):
Chi Wai Cheng, Dr, Principal Investigator, Affiliation: Department of Surgery, Division of Urology, North District Hospital/ The Chinese University of Hong Kong
Summary
The purpose of the study is to compare two alpha blockers, terazosin and doxazosin GITS, in
achieving a successful TWOC after AUR due to BPH, among Chinese males in Hong Kong, and in
delaying or avoiding a TURP.
Clinical Details
Official title: Randomized Trial Comparing Terazosin 5 mg Daily and Doxazosin GITS 4 mg Daily in the Successful Rate of Trial Without Catheter in Acute Urinary Retention With Long Term Follow up
Study design: Treatment, Randomized, Open Label, Placebo Control, Single Group Assignment, Safety/Efficacy Study
Primary outcome: Successful rate of Trial Without Catheter (TWOC) at phase 1Late failure of TWOC of, which is defined as recurrent of AUR or the need of invasive therapy among those who are successful in TWOC in phase 1
Secondary outcome: Proportion of subjects with hypotension or symptoms related to hypotension after administration of treatment drug for TWOCPeak flow rate (Qmax), voided volume (Vcomp) and post-voided residue volume (PVR)
Eligibility
Minimum age: 50 Years.
Maximum age: N/A.
Gender(s): Male.
Criteria:
Inclusion Criteria:
- Aged 50 or above
- Admitted for AUR due to BPH with PVR of 500 ml or more
Exclusion Criteria:
- Previous history of TURP
- Use of alpha blockers within recent 8 months
- Renal impairment (serum creatinine >140 umol/l)
- Poor premorbid state
Locations and Contacts
Prince of Wales Hospital, Hong Kong, China
Additional Information
HAREC Clinical Trial Registry
Starting date: October 2005
Ending date: November 2006
Last updated: June 16, 2008
|
